Development and Evaluation of a Prediction Model for Underestimated Invasive Breast Cancer in Women with Ductal Carcinoma In Situ at Stereotactic Large Core Needle Biopsy

被引:14
|
作者
Diepstraten, Suzanne C. E. [1 ]
van de Ven, Stephanie M. W. Y. [2 ]
Pijnappel, Ruud M. [1 ]
Peeters, Petra H. M. [3 ]
van den Bosch, Maurice A. A. J. [1 ]
Verkooijen, Helena M. [1 ]
Elias, Sjoerd G. [3 ]
机构
[1] Univ Med Ctr Utrecht, Dept Radiol, Utrecht, Netherlands
[2] Stanford Univ, Med Ctr, Dept Radiol, Stanford, CA 94305 USA
[3] Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands
来源
PLOS ONE | 2013年 / 8卷 / 10期
关键词
LYMPH-NODE BIOPSY; DIAGNOSIS; DISEASE; RISK; MICROCALCIFICATION; RECOMMENDATIONS; MANAGEMENT; IMPUTATION; SPECIMENS; LESIONS;
D O I
10.1371/journal.pone.0077826
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background: We aimed to develop a multivariable model for prediction of underestimated invasiveness in women with ductal carcinoma in situ at stereotactic large core needle biopsy, that can be used to select patients for sentinel node biopsy at primary surgery. Methods: From the literature, we selected potential preoperative predictors of underestimated invasive breast cancer. Data of patients with nonpalpable breast lesions who were diagnosed with ductal carcinoma in situ at stereotactic large core needle biopsy, drawn from the prospective COBRA (Core Biopsy after RAdiological localization) and COBRA2000 cohort studies, were used to fit the multivariable model and assess its overall performance, discrimination, and calibration. Results: 348 women with large core needle biopsy-proven ductal carcinoma in situ were available for analysis. In 100 (28.7%) patients invasive carcinoma was found at subsequent surgery. Nine predictors were included in the model. In the multivariable analysis, the predictors with the strongest association were lesion size (OR 1.12 per cm, 95% CI 0.98-1.28), number of cores retrieved at biopsy (OR per core 0.87, 95% CI 0.75-1.01), presence of lobular cancerization (OR 5.29, 95% CI 1.25-26.77), and microinvasion (OR 3.75, 95% CI 1.42-9.87). The overall performance of the multivariable model was poor with an explained variation of 9% (Nagelkerke's R-2), mediocre discrimination with area under the receiver operating characteristic curve of 0.66 (95% confidence interval 0.58-0.73), and fairly good calibration. Conclusion: The evaluation of our multivariable prediction model in a large, clinically representative study population proves that routine clinical and pathological variables are not suitable to select patients with large core needle biopsy-proven ductal carcinoma in situ for sentinel node biopsy during primary surgery.
引用
收藏
页数:8
相关论文
共 50 条
  • [21] Ductal carcinoma in situ: a risk prediction model for the underestimation of invasive breast cancer
    Park, Ko Woon
    Kim, Seon Woo
    Han, Heewon
    Park, Minsu
    Han, Boo-Kyung
    Ko, Eun Young
    Choi, Ji Soo
    Cho, Eun Yoon
    Cho, Soo Youn
    Ko, Eun Sook
    NPJ BREAST CANCER, 2022, 8 (01)
  • [22] Ductal carcinoma in situ: a risk prediction model for the underestimation of invasive breast cancer
    Ko Woon Park
    Seon Woo Kim
    Heewon Han
    Minsu Park
    Boo-Kyung Han
    Eun Young Ko
    Ji Soo Choi
    Eun Yoon Cho
    Soo Youn Cho
    Eun Sook Ko
    npj Breast Cancer, 8
  • [23] Lobular carcinoma in situ at stereotactic core-needle breast biopsy: Surgical biopsy correlation
    Shalmon, A
    Weinstein, J
    Gat, A
    Sperber, F
    Blank, A
    RADIOLOGY, 2002, 225 : 369 - 369
  • [24] Prediction of Sentinel Lymph Node Metastasis in Breast Ductal Carcinoma In Situ Diagnosed by Preoperative Core Needle Biopsy
    Zhang, Kai
    Qian, Lang
    Zhu, Qian
    Chang, Cai
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [25] Atypical ductal hyperplasia and ductal carcinoma in situ as revealed by large-core needle breast biopsy: Results of surgical excision
    Darling, MLR
    Smith, DN
    Lester, SC
    Kaelin, C
    Selland, DLG
    Denison, CM
    DiPiro, PJ
    Rose, DI
    Rhei, E
    Meyer, JE
    AMERICAN JOURNAL OF ROENTGENOLOGY, 2000, 175 (05) : 1341 - 1346
  • [26] Role of FDG-PET/CT in Prediction of Underestimation of Invasive Breast Cancer in Cases of Ductal Carcinoma In Situ Diagnosed at Needle Biopsy
    Shigematsu, Hideo
    Kadoya, Takayuki
    Masumoto, Norio
    Matsuura, Kazuo
    Emi, Akiko
    Kajitani, Keiko
    Amioka, Ai
    Okada, Morihito
    CLINICAL BREAST CANCER, 2014, 14 (05) : 358 - 364
  • [27] Role of FDG-PET/CT in prediction of underestimation of invasive breast cancer in cases of ductal carcinoma in situ diagnosed at needle biopsy
    Shigematsu, Hideo
    Kadoya, Takayuki
    Yoshimura, Noriko
    Kajitani, Keiko
    Emi, Akiko
    Masumoto, Noriko
    Haruta, Rumi
    Kataoka, Tsuyoshi
    Okada, Morihito
    CANCER RESEARCH, 2015, 75
  • [28] Predictors of residual invasive disease after core needle biopsy diagnosis of ductal carcinoma in situ
    Rutstein, Lisa A.
    Johnson, Ronald R.
    Poller, William R.
    Dabbs, David
    Groblewski, Jan
    Rakitt, Tina
    Tsung, Allan
    Kirchner, Thomas
    Sumkin, Jules
    Keenan, Donald
    Soran, Atilla
    Ahrendt, Gretchen
    Falk, Jeffrey S.
    BREAST JOURNAL, 2007, 13 (03): : 251 - 257
  • [29] Predictive biomarkers of invasive carcinoma on excision in patients with a diagnosis of ductal carcinoma in situ of the breast by needle biopsy
    Mori, Miki
    Krings, Gregor
    Chan, Loretta
    Wolf, Denise
    Chen, Yunn-Yi
    Kerlikowske, Karla
    Tlsty, Thea D.
    Coppe, Jean-Philippe
    Matsuda, Naoko
    Suzuki, Koyu
    Nakamura, Seigo
    van't Veer, Laura
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [30] The Finding of Invasive Cancer After a Preoperative Diagnosis of Ductal Carcinoma-In-Situ: Causes of Ductal Carcinoma-In-Situ Underestimates With Stereotactic 14-Gauge Needle Biopsy
    Lidewij E. Hoorntje
    Marguerite E. I. Schipper
    Petra H. M. Peeters
    Frank Bellot
    Remmert K. Storm
    Inne H. M. Borel Rinkes
    Annals of Surgical Oncology, 2003, 10 : 748 - 753